Supplementary Methods and Data from TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Tiara T. Byrd, Nabil Ahmed(Houston Methodist), Antonella Pignata, Nino Rainusso, Daniel Landi(Unknown), Joachim Koch(Johannes Gutenberg University Mainz), Meenakshi Hegde(Houston Methodist), Michael T. Lewis(Baylor College of Medicine), Matthew J. Ellis(University of California, Davis), Lacey E. Dobrolecki(Baylor College of Medicine), Htoo Zarni Oo(University of British Columbia), Brad St. Croix(National Cancer Institute), Winfried S. Wels(Goethe University Frankfurt), Benjamin Deneen(Baylor College of Medicine), Christopher Szot(Leidos (United States)), Steven Seaman(Frederick National Laboratory for Cancer Research), Vita S. Salsman, Kristen Fousek(National Cancer Institute), Poul H. Sorensen(University of British Columbia), Matthew L. Baker, Suzanne Z. Powell(Methodist Hospital), John Hicks, Heba Samaha, Bradley S. Fletcher, Kevin Bielamowicz
Cited by 0
Related Papers
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
|Nature|2017|853
A tutorial review of economic model predictive control methods
|Journal of Process Control|2014|711
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
|Journal of Clinical Investigation|2016|664